Norwegian ISP Altibox chooses Alinto's secure email platform to provide messaging services to its clients
31.5.2023 11:00:00 EEST | Business Wire | Press release
Norwegian ISP Altibox has decided to outsource its email platform to Alinto, with the aim of modernising its messaging services for 180 000 clients in the Nordics. The services provided are based on the SOGomail server and the Cleanmail security service, hosted by Alinto. This move happens a few months after the takeover of the SOGo open-source project by Alinto. It confirms the editors’ ability to address projects on an international scale and cover the whole email chain with GDPR-compliant solutions.
Modernisation of an email platform used by 180 000 clients
Until 2022, Altibox had a messaging platform built and operated in-house. As that platform started to require extensive maintenance operations, Altibox had to move to a new solution.
"We had two options : discontinue the service and delete all the emails – which was not acceptable from a client standpoint, or outsource our email services as we did not have any internal resources to create a new solution”, Marius Ekeland explains.
Thus, the company, which provides email services to 180 000 clients, decided to outsource to an external provider. “Email service is not our core business. We just need to deliver it in the correct way, with a secure manner”, Thomas Lunde adds.
Aligned on features, datacenter compliance and ecological expectations
After issuing an RFP, Altibox chose Alinto's solutions. The services provided are based on the SOGomail server and Cleanmail security service hosted by Alinto. The ISP appreciated the simplicity of the product and the operational stability of the Alinto solution. “Their package provides the best value for us, as it includes insights and access to support as well as an administration portal. This would give us the visibility we needed to properly run the service.
Also, the data centers’ locations are GDPR-compliant and have high ecological expectations. That is essential for us”, Thomas Lunde notes.
Meeting security and migration expectations
Security is of primary importance for Altibox. “The Cleanmail functionality is a big bonus for us because we are constantly strengthening the security of our services as an ISP. So, that matched our strategy”, Markus Ekeland confirms.
Migration of existing mailboxes was a big challenge with 180 terabytes of data to migrate. During migration Alinto’s teams came on-site. “The technical migration went smoothly. We migrated compressed data files, with some uncertainty about what would be the final volume, once uncompressed. Alinto had to make some short notice adjustments, and they proved to be very reactive. From my end, I am really happy because it is a big move”, Thomas Lunde adds.
Full press release:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005040/en/
Contact information
Additional information
Photos, logos, customer testimonials, press materials, set up of interviews on request to: Jessica Malia - Cabinet Gtec - rp@cabinet-gtec.fr - Tel. : +33(0) 4 56 40 67 26 - www.cabinet-gtec.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom